Late-Cycle Meeting: The PDUFA V Goal Letter
This article was originally published in RPM Report
The following text is the description of the late-cycle meeting in the “goal letter” negotiated by FDA and the pharmaceutical industry in advance of the Prescription Drug User Fee Act reauthorization.
You may also be interested in...
Anand Shah returns to FDA as deputy commissioner; like Abernethy, he is an oncologist with a background in big data.
Resubmission comes more than four years after Purdue pulled an sNDA seeking to demonstrate ‘real-world’ abuse prevention.
FDA has been criticized in recent months for approving drugs too quickly, based on insufficient evidence. The agency’s oncology chief Richard Pazdur fights back.